Former head of gRED Varney joining Erasca; plus AAM, City of Hope, Immunovant, Kura, Illumina and more
Former head of gRED Michael Varney is joining cancer company Erasca Inc. as chairman of R&D and a scientific advisory board member. Varney retired in July after 15 years at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY), where for the past five years he led the Genentech Research and Early Development unit and was a member of the executive committee of Roche (SIX:ROG; OTCQX:RHHBY). In April, Arch Venture Partners and Cormorant Asset Management co-led the San Diego-based company’s $200 million series B round, one of the year’s largest venture rounds (see “$200M Megaround for Erasca”).
The Association for Accessible Medicines said Dan Leonard joined as president and CEO, succeeding Chester Davis who left in February. Leonard was president and CEO of the National Pharmaceutical Council. The AAM represents generics and biosimilar manufacturers. ...